1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Pentair said preliminary second-quarter 2026 sales are about $930 million, down 17% from its prior guidance of up about 1%, mainly because of Pool channel inventory destocking. It cut full-year 2026 adjusted EPS guidance to $4.60 to $4.80 from $5.30 to $5.40, and said CFO Nicholas Brazis resigned on July 10, 2026, with Robert Fishman named interim CFO.
Q2 2026 preliminary sales of about $930 million, down 17% versus prior guidance of up about 1%
Q2 2026 adjusted EPS of about $1.12 versus prior guidance of $1.47 to $1.50; GAAP EPS of about $0.80
Full-year 2026 adjusted EPS guidance cut to $4.60 to $4.80 from $5.30 to $5.40; full-year sales now expected down 4% to 7%
CFO Nicholas Brazis resigned July 10, 2026; Robert Fishman appointed interim CFO with a $125,000 monthly salary
HCA Healthcare preliminarily reported second-quarter 2026 revenues of $20.230 billion and net income of $1.699 billion, or $7.62 per diluted share, both up from the year-earlier quarter. The company also lowered its 2026 net income and EPS guidance, citing a payer mix shift from health insurance exchange coverage losses, which shareholders should weigh against the stronger quarter. The preliminary figures are unaudited and subject to final quarterly closing procedures.
Q2 2026 revenues about $20.230 billion vs. $18.605 billion in Q2 2025; net income $1.699 billion ($7.62 per diluted share) vs. $1.653 billion ($6.83).
2026 diluted EPS guidance lowered to $28.70 to $30.50 from $29.10 to $31.50; net income guidance lowered to $6.300 billion to $6.700 billion from $6.495 billion to $7.035 billion.
Q2 unfavorable payer mix impact from exchange coverage losses estimated at about $400 million, partly offset by about $400 million of incremental Medicaid Supplemental Payment Program benefit.
Second-quarter earnings call scheduled for Friday, July 24, 2026, at 9:00 a.m. Central Time.
AngioDynamics reported fiscal 2026 results for the year ended May 31, 2026, with pro forma net sales up 9.4% to $320.2 million and Med Tech sales up 18.4% to $150.0 million. The GAAP net loss widened to $36.7 million, or $0.88 per share, from $34.0 million, or $0.83, a year earlier, and the company issued fiscal 2027 guidance calling for net sales of $336.0 million to $341.0 million and adjusted loss per share of $0.29 to $0.24.
Fourth-quarter pro forma net sales were $86.6 million, up 8.0%, but the GAAP loss per share was $0.27 versus $0.15 a year earlier.
Full-year adjusted EBITDA was $13.2 million, compared with $7.6 million in the prior year.
Fiscal 2027 guidance: net sales of $336.0 million to $341.0 million and adjusted EPS of ($0.29) to ($0.24), compared with fiscal 2026 adjusted loss per share of $0.24.
The company ended fiscal 2026 with $53.9 million in cash and states it has a debt-free balance sheet.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.